Longevity Pipeline
Dorian Therapeutics
USP7 inhibition (senolytic) · Musculoskeletal aging
IND-enablingSenolytics
Mechanism
USP7 inhibition (senolytic)
Intervention class
Small molecule senolytic
Indication
Musculoskeletal aging
Stage
IND-enabling
Evidence
animal
Funding
VC / NIA grants
Backers
Various
Overview
Next-gen senolytics targeting USP7 to clear senescent cells with a wider therapeutic window than first-gen agents.
Technology
Dorian Therapeutics works in Senolytics — Drugs that hunt down and kill the 'zombie' cells that drive aging.
Read the Senolytics brief →Related companies
Calico
Multiple (cellular senescence, neurodeg.)
Unity Biotechnology
Bcl-xL inhibition (senolytic)
Insilico Medicine
TNIK inhibition (anti-fibrotic / senescence)
Cambrian BioPharma
Multiple (mitophagy, senescence, mTOR)
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.